Department of Health and Social Care

The Government recognises the devastating impact of sudden unexplained death in childhood (SUDC) on affected families and communities. As the Minister for Public Health and Prevention (Sharon Hodgson MP) set out during a recent Westminster Hall Debate on this issue on 24 March 2026, the Government’s is committed to strengthening pathology services, ensuring high-quality bereavement support and growing the evidence base around SUDC.

Parents who have lost a child to SUDC should be able to access the advice and support that they need. Bereavement support is available on the NHS help page and GOV.UK website in an online-only format.

NHS Bereavement support is commissioned locally, allowing services to be shaped around the needs of local communities. For anyone seeking help after a bereavement, we encourage them to speak to their general practitioner, who can advise on and refer into local bereavement support services. My officials are exploring opportunities to include signposting on the NHS website to SUDC UK to ensure families have access to information when they need it most.

The Government recognises the devastating impact of sudden unexplained death in childhood (SUDC) on affected families and communities. As the Minister for Public Health and Prevention (Sharon Hodgson MP) set out during a recent Westminster Hall Debate on this issue on 24 March 2026, the Government’s is committed to strengthening pathology services, ensuring high-quality bereavement support and growing the evidence base around SUDC.

Parents who have lost a child to SUDC should be able to access the advice and support that they need. Bereavement support is available on the NHS help page and GOV.UK website in an online-only format.

NHS Bereavement support is commissioned locally, allowing services to be shaped around the needs of local communities. For anyone seeking help after a bereavement, we encourage them to speak to their general practitioner, who can advise on and refer into local bereavement support services. My officials are exploring opportunities to include signposting on the NHS website to SUDC UK to ensure families have access to information when they need it most.

We're setting the Advice and Guidance (A&G) clock start so it's the same as outpatient referrals, ensuring no patient will have to wait longer for an appointment as a result of A&G

As set out in the Medium Term Planning Framework, the National Health Service will move toward delivering care through a ‘Single Point of Access’ (SPoA) for all appropriate requests and referrals, excluding for urgent suspected cancer. Under the new SPoA model, if a patient needs treatment, their Referral to Treatment (RTT) clock start date will be calculated from the date the Advice and Guidance (A&G) request or referral was received by the SPoA. This is instead of the current process for A&G, where the clock start date is the date that the request or referral is converted to a treatment pathway. This will ensure that patients' waiting times are accurately reflected.

In February 2026, NHS England issued The Elective Single Point of Access: Technical Guidance for 2026/27 to integrated care boards. This provides guidance on RTT rules and quality assurance arrangements, and advice on establishing leadership and governance structures that ensure SPoA outcomes are assessed regularly. The SPoA will be supported by improvements to the NHS e-Referral Service, which will enable NHS England to collect data on triage outcomes.

SPoA is designed to promote clinical collaboration between primary care referrers and secondary care clinicians, including by facilitating two-way communication and shared decision making. General practitioners (GPs) can re-submit a referral following a SPoA triage outcome if they have concerns about the clinical decision. Escalation routes for concerns about triage decisions will continue to operate through locally agreed referral pathways and communication processes for GPs and patients, supported by improvements to the NHS e-Referral Service. Where patients have concerns regarding outcomes, local Patient Advice and Liaison Service teams can provide advice and support.

We're setting the Advice and Guidance (A&G) clock start so it's the same as outpatient referrals, ensuring no patient will have to wait longer for an appointment as a result of A&G

As set out in the Medium Term Planning Framework, the National Health Service will move toward delivering care through a ‘Single Point of Access’ (SPoA) for all appropriate requests and referrals, excluding for urgent suspected cancer. Under the new SPoA model, if a patient needs treatment, their Referral to Treatment (RTT) clock start date will be calculated from the date the Advice and Guidance (A&G) request or referral was received by the SPoA. This is instead of the current process for A&G, where the clock start date is the date that the request or referral is converted to a treatment pathway. This will ensure that patients' waiting times are accurately reflected.

In February 2026, NHS England issued The Elective Single Point of Access: Technical Guidance for 2026/27 to integrated care boards. This provides guidance on RTT rules and quality assurance arrangements, and advice on establishing leadership and governance structures that ensure SPoA outcomes are assessed regularly. The SPoA will be supported by improvements to the NHS e-Referral Service, which will enable NHS England to collect data on triage outcomes.

SPoA is designed to promote clinical collaboration between primary care referrers and secondary care clinicians, including by facilitating two-way communication and shared decision making. General practitioners (GPs) can re-submit a referral following a SPoA triage outcome if they have concerns about the clinical decision. Escalation routes for concerns about triage decisions will continue to operate through locally agreed referral pathways and communication processes for GPs and patients, supported by improvements to the NHS e-Referral Service. Where patients have concerns regarding outcomes, local Patient Advice and Liaison Service teams can provide advice and support.

The Government remains committed to looking for opportunities to implement artificial intelligence (AI) in cancer services to speed up diagnosis, improve treatment efficacy, and reduce treatment side effects where possible. We have demonstrated this commitment through a £133 million investment in the AI in Health and Care Award, which has funded innovations relevant to prostate cancer diagnosis and treatment that align with the NHS Long Term Plan.

While AI is already being used to support diagnostic and treatment pathways, any future use of AI intended to further improve radiotherapy services, will be carefully evaluated to ensure safety, efficacy, and clinical benefit and benchmarked against existing standards and approaches.

The Government’s recently published National Cancer Plan sets out how we will modernise the National Health Service and utilise AI to support faster radiotherapy planning, provide more accurate contouring, improve productivity, and free up clinicians’ time to focus on patient care. Over the next decade, we will harness AI to help the NHS to deliver more personalised and responsive cancer care.

The Government is committed to publishing a 10 Year Workforce Plan to set out action to create a workforce ready to deliver the transformed service set out in the 10-Year Health Plan. The 10 Year Workforce Plan will ensure the National Health Service has the right people in the right places, with the right skills to care for patients, when they need it. This workforce plan will set out how we will deliver that change by making sure that staff are better treated, have better training, more fulfilling roles, and hope for the future.

We are investing £485 million in general practices (GPs) in 2026/27, bringing the total spend on the GP Contract to over £13.8 billion. This builds on the £1.1 billion boost in investment in 2025/26. As part of the 26/27 GP Contract, we are increasing flexibility of the Additional Roles Reimbursement Scheme (ARRS) by removing the restriction that ARRS funding can only be used for recently qualified GPs, increasing the maximum reimbursement amount for GP roles to reflect experience, and enabling primary care networks to recruit a broader range of ARRS roles, where agreed with the commissioner.

Following feedback from the 2026/27 GP Contract consultation, we are introducing a practice-level GP reimbursement scheme which ring-fences and repurposes £292 million of funding from the current Capacity and Access Payment. This funding will be available to practices to hire additional GPs or fund additional sessions with existing GPs to improve access in practices. This aims to strengthen capacity, access, and improve patient satisfaction, whilst also addressing GP unemployment and underemployment.

We know that the way core GP funding is allocated across England is considered outdated and we recognise the importance of ensuring funding for core services is distributed equitably between practices across the country. This is why we are currently reviewing the GP funding formula, the Carr-Hill formula, to ensure that resources are targeted where they are most needed.

The first phase of the review is expected to conclude in March 2026. Subject to ministerial decision, further work would be undertaken to technically develop and model any proposed changes to the formula. Findings from the review will be published in due course by the National Institute for Health and Care Research.

The proposal has been received and Government officials will assess it in the normal manner.

The resilience of United Kingdom supply chains is a key priority, and the Department and NHS England are committed to helping to build long term supply chain resilience for medicines. We recognise the importance of ensuring a resilient and reliable supply of medical isotopes and how important that is for patients and for the National Health Service. We regularly engage with industry partners to support continued supply of medical radioisotopes to the NHS, including responding to supply disruptions. The Department is working with the NHS and other parts of the Government to better understand future needs for medical radioisotopes.

In respect to isotope production and associated research in the UK, the Government has made up to £520 million available through the Life Sciences Innovative Manufacturing Fund to support UK manufacture of medicine and medical technology products. This includes applications looking to establish, expand, or improve UK-based manufacture of medical radioisotopes for diagnostic or therapeutic applications. In addition, last year, the Government also announced a £54 million funding package for eight innovative research and development projects, including £9.9 million earmarked for Project Alpha to explore how to make medical treatments from legacy nuclear material, something that could unlock the UK’s potential to develop promising new cancer therapies.

The Department remains committed to ensuring that all patients have timely access to cutting-edge cancer treatments, including radiotherapy. This commitment has been demonstrated by a £70 million investment into 28 new LINAC radiotherapy machines, which are currently being rolled out and replacing outdated, inefficient radiotherapy equipment. These new machines will reduce waiting times and increase treatment capacity by 15%, enabling an additional 27,500 patients to be treated each year.

We expect that local systems will continue to look for opportunities to streamline radiotherapy treatment services, improve treatment availability, and harness artificial intelligence technology to support oncologists to plan radiotherapy treatments faster and more accurately.

The Neighbourhood Health Framework is designed to provide clarity and consistency to integrated care boards (ICBs), local authorities, and their partners, in developing and scaling neighbourhood health.

It is important that reforms are locally led, as ICBs and local authorities are best placed to design services that make sense for their local populations. Local systems can choose to go further than the minimum aims set out in the framework, and this could include a focus on chronic kidney disease.

Early diagnosis of chronic kidney disease is supported through widespread access to blood and urine tests across the National Health Service, including in primary care and community diagnostic services.

The Government recognises that migraine is a serious and often debilitating neurological condition, with a wide range of symptoms that go far beyond a headache. Migraine attacks can be a whole-body experience that can make it difficult to function normally.

The Royal College of General Practitioners has developed two e-learning modules on migraine and cluster headaches, which aim to raise awareness amongst primary care clinicians about the different types of migraine and their associated symptoms, and how to differentiate.

The Getting It Right First Time programme for Neurology published a National Speciality Report, which makes several recommendations in relation to improving recognition and diagnosis of migraine by general practitioners. Additionally, the RightCare Headache and Migraine Toolkit sets out key priorities for improving care for patients with migraine, which includes correct identification and diagnosis of headache disorders.

The National Institute for Health and Care Excellence guideline, Headaches in over 12s: diagnosis and management, sets out best practice for healthcare professionals in the care, treatment, and support of people who suffer from headaches, including migraine. It aims to improve the recognition and management of headaches and migraine.

NHS England’s national Stroke Programme has undertaken work to understand the value and impact of six‑month post‑stroke reviews, particularly through the development of the Integrated Community Stroke Service (ICSS) model and the Stroke Quality Improvement in Rehabilitation (SQuIRe) programme.

Overall, the emerging evidence demonstrates that six‑month reviews are likely to provide a positive mechanism for identifying unmet need, enabling personalised care, and supporting longer‑term recovery and self‑management. The learning from SQuIRe continues to inform the national ICSS model and future commissioning guidance.

The ICSS model includes tailored, patient-centred reablement care. As part of this, through the SQuIRe programme, NHS England has funded several projects testing models of delivery of six month reviews, working closely with third sector partners, such as the Stroke Association. Analysis of these projects is pending.

NHS England’s national Stroke Programme has undertaken work to understand the value and impact of six‑month post‑stroke reviews, particularly through the development of the Integrated Community Stroke Service (ICSS) model and the Stroke Quality Improvement in Rehabilitation (SQuIRe) programme.

Overall, the emerging evidence demonstrates that six‑month reviews are likely to provide a positive mechanism for identifying unmet need, enabling personalised care, and supporting longer‑term recovery and self‑management. The learning from SQuIRe continues to inform the national ICSS model and future commissioning guidance.

The ICSS model includes tailored, patient-centred reablement care. As part of this, through the SQuIRe programme, NHS England has funded several projects testing models of delivery of six month reviews, working closely with third sector partners, such as the Stroke Association. Analysis of these projects is pending.

NHS England commissions the specialised elements of motor neurone disease (MND) care that patients may receive from 27 specialised neurology centres across England. Within these specialised centres, neurological multidisciplinary teams ensure patients can access a range of health professionals and specialised treatment and support, according to their needs.

At the national level, there are a number of initiatives supporting service improvement and better care for patients with MND, including the Getting It Right First Time Programme for Neurology and the RightCare Progressive Neurological Conditions Toolkit.

Baroness Casey has set out that the Government must take immediate action on MND. Where someone has a severe, reasonably predictable, and life-limiting condition, it is essential that we provide rapid access to the support they need, and we will take forward immediate work to develop a fast-track process, or “passport”, that speeds up assessments and access to care for people diagnosed with MND. We will consider how best to safely implement a process that expedites assessments and gets people with MND the care and support they need more quickly.

The Government has provided £6 million in funding for the MND Translational Accelerator, which aims to speed up the development of treatments for MND, and £2 million in funding for the MND Data Catalyst, to accelerate the discovery of new diagnostics, treatments, and support better care for MND patients. Twelve projects have been funded through the accelerator, and all aimed at speeding up the development of treatments for MND.

The Government has also invested £8 million through the National Institute for Health and Care Research for the EXPERTS-ALS study, a pre-clinical study which is designed to accelerate the identification and testing of the most promising treatment candidates for treating amyotrophic lateral sclerosis, the most common form of MND.

Local authorities have duties to support people caring for their family and friends. The Care Act 2014 requires local authorities to deliver a wide range of high-quality care and support services, including support for unpaid carers.

The Government recognises the vital role of unpaid carers and is committed to ensuring they have the support they need. Through measures in the 10-Year Health Plan, we are equipping and supporting carers by making them more visible, empowering their voices in care planning, joining up services, and streamlining their caring tasks by introducing a new ‘MyCarer’ section to the NHS App.

NHS England commissions the specialised elements of motor neurone disease (MND) care that patients may receive from 27 specialised neurology centres across England. Within these specialised centres, neurological multidisciplinary teams ensure patients can access a range of health professionals and specialised treatment and support, according to their needs.

At the national level, there are a number of initiatives supporting service improvement and better care for patients with MND, including the Getting It Right First Time Programme for Neurology and the RightCare Progressive Neurological Conditions Toolkit.

Baroness Casey has set out that the Government must take immediate action on MND. Where someone has a severe, reasonably predictable, and life-limiting condition, it is essential that we provide rapid access to the support they need, and we will take forward immediate work to develop a fast-track process, or “passport”, that speeds up assessments and access to care for people diagnosed with MND. We will consider how best to safely implement a process that expedites assessments and gets people with MND the care and support they need more quickly.

The Government has provided £6 million in funding for the MND Translational Accelerator, which aims to speed up the development of treatments for MND, and £2 million in funding for the MND Data Catalyst, to accelerate the discovery of new diagnostics, treatments, and support better care for MND patients. Twelve projects have been funded through the accelerator, and all aimed at speeding up the development of treatments for MND.

The Government has also invested £8 million through the National Institute for Health and Care Research for the EXPERTS-ALS study, a pre-clinical study which is designed to accelerate the identification and testing of the most promising treatment candidates for treating amyotrophic lateral sclerosis, the most common form of MND.

Local authorities have duties to support people caring for their family and friends. The Care Act 2014 requires local authorities to deliver a wide range of high-quality care and support services, including support for unpaid carers.

The Government recognises the vital role of unpaid carers and is committed to ensuring they have the support they need. Through measures in the 10-Year Health Plan, we are equipping and supporting carers by making them more visible, empowering their voices in care planning, joining up services, and streamlining their caring tasks by introducing a new ‘MyCarer’ section to the NHS App.

NHS England commissions the specialised elements of motor neurone disease (MND) care that patients may receive from 27 specialised neurology centres across England. Within these specialised centres, neurological multidisciplinary teams ensure patients can access a range of health professionals and specialised treatment and support, according to their needs.

At the national level, there are a number of initiatives supporting service improvement and better care for patients with MND, including the Getting It Right First Time Programme for Neurology and the RightCare Progressive Neurological Conditions Toolkit.

Baroness Casey has set out that the Government must take immediate action on MND. Where someone has a severe, reasonably predictable, and life-limiting condition, it is essential that we provide rapid access to the support they need, and we will take forward immediate work to develop a fast-track process, or “passport”, that speeds up assessments and access to care for people diagnosed with MND. We will consider how best to safely implement a process that expedites assessments and gets people with MND the care and support they need more quickly.

The Government has provided £6 million in funding for the MND Translational Accelerator, which aims to speed up the development of treatments for MND, and £2 million in funding for the MND Data Catalyst, to accelerate the discovery of new diagnostics, treatments, and support better care for MND patients. Twelve projects have been funded through the accelerator, and all aimed at speeding up the development of treatments for MND.

The Government has also invested £8 million through the National Institute for Health and Care Research for the EXPERTS-ALS study, a pre-clinical study which is designed to accelerate the identification and testing of the most promising treatment candidates for treating amyotrophic lateral sclerosis, the most common form of MND.

Local authorities have duties to support people caring for their family and friends. The Care Act 2014 requires local authorities to deliver a wide range of high-quality care and support services, including support for unpaid carers.

The Government recognises the vital role of unpaid carers and is committed to ensuring they have the support they need. Through measures in the 10-Year Health Plan, we are equipping and supporting carers by making them more visible, empowering their voices in care planning, joining up services, and streamlining their caring tasks by introducing a new ‘MyCarer’ section to the NHS App.

The Government is committed to improving the lives of those living with rare diseases, and we acknowledge unmet need remains, with just 5% of rare diseases having an approved and effective treatment. The UK Rare Diseases Framework sets out four priorities collaboratively developed with the rare disease community, such as improving access to specialist care, treatments, and drugs, including in Slough. We published the fifth annual England action plan in February 2026, where we report on the steps we have taken to advance these priorities. These include:

• the Medicines and Healthcare products Regulatory Agency (MHRA) developing a framework to enable innovation in rare disease therapies;
• new clinical trial regulations being fully implemented from April 2026;
• the MHRA and the National Institute for Health and Care Excellence (NICE) aligning a pathway for parallel decision making to reduce the gap between marketing authorisation and NICE guidance decisions;
• continuing to review the effectiveness of the Early Access to Medicines Scheme, the Innovative Licensing and Access Pathway and the Innovative Medicines Fund, access pathways for rare therapies; and
• NHS England progressing work to develop an operational framework for individualised therapies.

No specific guidance has been issued on recording suspected topical steroid withdrawal in patient medical records, including to general practitioners. The Medicines and Healthcare products Regulatory Agency has issued guidance documents on topical steroid withdrawal, which are available at the following two links:

https://www.gov.uk/drug-safety-update/topical-corticosteroids-information-on-the-risk-of-topical-steroid-withdrawal-reactions

https://www.gov.uk/drug-safety-update/topical-steroids-introduction-of-new-labelling-and-a-reminder-of-the-possibility-of-severe-side-effects-including-topical-steroid-withdrawal-reactions

The National Institute for Health and Care Excellence has also published guidance, which is available at the following link:

https://cks.nice.org.uk/topics/corticosteroids-topical-skin-nose-eyes/management/topical-skin-treatment/

I refer the Hon. Member to the answer I gave on 31 March 2026 to Question 122732.

The Yellow Card scheme collects reports of suspected adverse drug reactions, medical device incidents, and concerns about the safety and quality of medicines. Where appropriate, reports raising potential counterfeit, compliance, or safety issues may be referred to relevant teams within the Medicines and Healthcare products Regulatory Agency (MHRA) for consideration of regulatory or enforcement action.

However, this information is not held in a format that readily allows the MHRA to identify how many reports submitted by members of the public resulted in enforcement action in relation to counterfeit medicines, unapproved medicines in the UK, and medicines which are authorised for supply in the United Kingdom but supplied through unregulated channels. Extracting this information from Yellow Card reports would require a manual review of individual records and would incur disproportionate cost. The MHRA is therefore unable to provide the requested figures for each of the past five years.

The NHS Health Check, a core component of England’s cardiovascular disease (CVD) prevention programme, has been commissioned by local authorities in England since 2013, and engaged over 1.4 million people last year. Local authorities are responsible for commissioning the NHS Health Check, including setting accountability measures for integrated care boards regarding delivery of the programme.

To accelerate progress on the Government’s ambition to reduce premature mortality from heart disease and stroke by 25% in the next ten years, we will publish a new Cardiovascular Disease Modern Service Framework (CVD MSF) this spring.

The CVD MSF will support consistent, high quality, and equitable activity across the CVD pathway by identifying and setting standards for the best evidenced interventions. As part of this, Department officials are working closely with NHS England and stakeholders and are assessing accountability measures.

Sports and cultural events can cover a variety of activities, sizes, and attendee numbers, so there is no one specific definition within the Care Quality Commission’s regulation. However, where treatment of disease, disorder, or injury (TDDI) care is deemed necessary, the amendment will mean an event organiser is safe in the knowledge that the TDDI care acquired through a provider is regulated.

This activity covers a treatment that is provided by, or under the supervision of, a defined list of healthcare professionals or by a multi-disciplinary team that includes a listed healthcare professional, or is provided by, or under the supervision of, a social worker where the treatment is for a mental disorder, or by a multi-disciplinary team that includes a social worker where the treatment is for a mental disorder, for a disease, disorder, or injury. TDDI covers a wide range of treatments. It includes examples such as:

• emergency treatment;
• ongoing treatment for long-term conditions;
• treatment for a physical or mental health condition or learning disability;
• giving vaccinations or immunisations; and/or
• palliative care.

The Department, in consultation with the Care Quality Commission (CQC), has agreed that there will be a phased approach to implementing the updated regulations. This is so:

• providers have sufficient time to prepare to submit their CQC registration applications and ensure compliance with the regulations;
• to prevent undue disruption to the events sector; and
• to allow the CQC time to prepare for the receipt of additional registration applications and to enable them to process those applications in a timely manner whilst at the same time fulfilling their existing regulatory obligations.

The CQC will produce guidance that sets out the date that providers would have to apply to be registered by. This aims to prevent a backlog caused by last-minute applications.

For applications received on or by this date that are fully complete at the time of submission to allow for validation, the CQC will take all reasonable steps to undertake assessment and advise providers of the outcome of their application on or before December 2027.

Following the Penny Dash Review, the CQC accepted the high‑level recommendations, including stabilising its regulatory platform and improving the registration experience for providers. The Department meets the CQC regularly to discuss the progress of its improvements.

The de minimis assessment for the regulation amendment was published alongside the draft statutory instrument and explanatory memorandum, and is available at the following link:

https://www.legislation.gov.uk/ukdsi/2026/9780348279955/resources

House debates on the statutory instrument are expected to commence soon.

To tackle unwarranted variation and support consistent, high-quality care across the cardiovascular disease pathway, and to support the Government’s ambition to reduce premature deaths from heart disease and stroke by 25% within a decade, the Government will publish a new cardiovascular disease Modern Service Framework (CVD MSF) this spring.

In developing the CVD MSF, we are reviewing evidence and engaging stakeholders on a range of pathway areas, including lipid management. The framework will support integrated care boards by identifying the best-evidenced interventions and setting clear implementation standards. This approach will help ensure greater consistency in the detection, treatment, and management of cardiovascular disease.

We recognise the substantial economic and National Health Service burden of migraine, alongside the personal impacts. We know that there are an estimated 16,500 emergency admissions per year for migraine that could be avoided, costing the NHS £11.5 million.

At the national level, there are a number of initiatives supporting service improvement and better care for patients with migraine such as the Getting It Right First Time (GIRFT) Programme for Neurology, the RightCare Headache and Migraine Toolkit, and the Neurology Transformation Programme.

The Neurology Transformation Programme is strengthening integrated headache pathways, supporting integrated care boards to deliver consistent, timely migraine care closer to home. The RightCare Headache and Migraine Toolkit also gives systems a clear blueprint for earlier diagnosis, better long‑term management, and reducing unwarranted variation.

The GIRFT Programme is also working to standardise care, promote better use of preventive treatments, and reduce reliance on accident and emergency for migraine crises by empowering general practices to manage headache disorders effectively.

We recognise the substantial economic and National Health Service burden of migraine, alongside the personal impacts. We know that there are an estimated 16,500 emergency admissions per year for migraine that could be avoided, costing the NHS £11.5 million.

At the national level, there are a number of initiatives supporting service improvement and better care for patients with migraine such as the Getting It Right First Time (GIRFT) Programme for Neurology, the RightCare Headache and Migraine Toolkit, and the Neurology Transformation Programme.

The Neurology Transformation Programme is strengthening integrated headache pathways, supporting integrated care boards to deliver consistent, timely migraine care closer to home. The RightCare Headache and Migraine Toolkit also gives systems a clear blueprint for earlier diagnosis, better long‑term management, and reducing unwarranted variation.

The GIRFT Programme is also working to standardise care, promote better use of preventive treatments, and reduce reliance on accident and emergency for migraine crises by empowering general practices to manage headache disorders effectively.

Early diagnosis is a key focus of the National Cancer Plan. It is a priority for the Government to support the National Health Service to diagnose cancer, including blood cancers, as early and quickly as possible, and to treat it faster, to improve outcomes.

To tackle the late diagnoses of blood cancers including leukaemia, the NHS is implementing non-specific symptom pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers, including leukaemia, are one of the most common cancer types diagnosed through these pathways.

The NHS will improve early diagnosis and quicker treatment of blood cancers, including leukaemia, by expanding diagnostic services with investments in magnetic resonance imaging and computed tomography scanners. Furthermore, the 10-Year Health Plan’s commitment to putting digital health at the heart of the future health service and integrating that with a single patient record and neighbourhood health services, will mean that cancer patients will get the joined-up care they deserve.

For providers of treatment of disease, disorder, or injury (TDDI), regulatory obligations do not vary by event type or the number of attendees. Restricting Care Quality Commission (CQC) regulation to larger events would risk unregulated providers operating at events where attendance is higher than anticipated and would create gaps in oversight at smaller events that may also require TDDI services.

The level of risk associated with an event cannot be determined by attendance figures alone. Event organisers are expected to draw on risk assessments, advice from Statutory Advisory Groups, and sector guidance such as the Purple and Green Guides to identify the appropriate level of event healthcare provision.

If, following this process, an organiser determines that first aid is sufficient for a small event, this position is unaffected. First aid does not fall within the definition of TDDI and will remain outside CQC regulation.

The Government is committed to ensuring that anyone with a drug or alcohol problem can access the help and support they need, and we recognise the need for evidence-based, high-quality treatment.

Local authorities are responsible for assessing local need for alcohol and drug prevention and treatment in their area and for commissioning services to meet these needs. Through the Public Health Grant, we are providing local authorities with £3.4 billion in ringfenced funding over the next three years for drug and alcohol treatment and recovery. This first multi-year settlement in over a decade gives local authorities the certainty to plan and invest for the medium term.

Additionally, the Department provides guidance and support to improve outcomes, for example last year we launched a self-assessment toolkit to help local areas to improve residential drug and alcohol treatment, which is available at the following link:

https://www.gov.uk/government/publications/residential-drug-and-alcohol-treatment-self-assessment-toolkit

The Department also maintains regular engagement with commissioners and providers and works closely with other Government departments to improve pathways into treatment and foster recovery.

While the Department does not ring-fence integrated care board (ICB) funding exclusively for prostate cancer public awareness campaigns, community-level engagement programmes aimed at increasing awareness and early detection are supported via broader communication programmes, working in partnership with charities and local Cancer Alliances.

To increase knowledge of cancer symptoms, and to address barriers to acting on them, the National Health Service has run Help Us Help You campaigns. These campaigns focused on recognising a range of symptoms, as well as encouraging body awareness, to help people spot symptoms across a wide range of cancers, including prostate cancer, at an earlier stage. NHS England and other NHS organisations, nationally and locally, publish information on the signs and symptoms of many different types of cancer, including prostate cancer. This information can be found at sources including the NHS website, which is available at the following link:

https://www.nhs.uk/

The National Cancer Plan, published in February 2026, is backed by significant funding committed by the Government at the Spending Review, including £200 million next year for local Cancer Alliances. Alliances are encouraged to allocate a proportion of this funding to the delivery of local early diagnosis plans, to drive progress on data-led priorities. This can include work to support the diagnosis of prostate cancer, but it will vary by alliance depending on local need. In 2025/26, several alliances have undertaken work to support awareness and earlier diagnosis of prostate cancer.

There are many foods that people might be allergic to, but the current list of 14 allergens, defined in legislation, are those established as the most common allergenic ingredients or processing aids of public health concern across Europe. They must be clearly identified on prepacked foods and communicated effectively when eating out. Foods like pine nuts are not classified as tree nuts and as such are not named in the regulations.

The Food Standards Agency (FSA) is working with the British Society for Allergy and Clinical Immunology and other stakeholders to gather more information on hidden and emerging food allergens, which will help assess the need for further research and work in this area. Any change to the current list of the 14 mandated allergens would need to be supported by robust evidence and thoroughly assessed.

The FSA continues to monitor the situation closely but at present there are no plans to amend the regulated list of 14 allergens. It advises those with an allergy or intolerance to foods outside of the mandated allergens should be able to check the ingredients list and avoid foods they need to, and in restaurants they should ask the person serving them if the food they wish to avoid is used in any of the dishes to make the right choices.

Securing appropriate placements and clinical support for patients sits with the relevant integrated care boards (ICBs), which commission and fund the individual packages of care. NHS England’s regional specialised commissioning teams work closely with ICBs to provide clinical oversight and advice, including on the neuropsychiatric and neuro‑rehabilitation needs of patients with acquired brain injury. This includes supporting commissioners to identify suitable services, ensuring placements meet required clinical standards, and advising on safe transition planning from the independent sector.

ICBs remain accountable for arranging and maintaining placements that provide the right multidisciplinary expertise. NHS England engages with local systems, including in Northampton, to ensure that any moves are clinically appropriate, safe, and consistent with national expectations for specialised neurological care.

The Government is guided by the independent scientific advice of the UK National Screening Committee (UK NSC). The UK NSC makes its recommendations based on internationally recognised criteria and a rigorous evidence review and consultation process. Where the committee is confident that offering screening provides more good than harm, they recommend a screening programme.

The UK NSC last reviewed screening for the conditions associated with sudden cardiac death in people aged under 39 years old in 2019. The conclusion of that review was that population screening should not be offered, as research showed that current tests are not accurate enough to use on young people with no symptoms.

The Department and NHS England currently have no specific ongoing campaigns, or plans to conduct a campaign, to encourage cardiac screening in young people as this would go against the current evidence-based advice.

The Government recognises that migraine is a serious and often debilitating neurological condition, with a wide range of symptoms that go far beyond a headache. Migraine attacks can be a whole-body experience that can make it difficult to function normally.

The Royal College of General Practitioners has developed two e-learning modules on migraine and cluster headaches, which aim to raise awareness amongst primary care clinicians about the different types of migraine and their associated symptoms, and how to differentiate.

The Getting It Right First Time programme for Neurology published a National Speciality Report, which makes several recommendations in relation to improving recognition and diagnosis of migraine by general practitioners. Additionally, the RightCare Headache and Migraine Toolkit sets out key priorities for improving care for patients with migraine, which includes correct identification and diagnosis of headache disorders.

The National Institute for Health and Care Excellence guideline, Headaches in over 12s: diagnosis and management, sets out best practice for healthcare professionals in the care, treatment, and support of people who suffer from headaches, including migraine. It aims to improve the recognition and management of headaches and migraine.

The Single Point of Access (SPoA) triage process is consistent with Jess’s Rule.

Jess’s Rule is an NHS England patient safety initiative for primary care. It is designed for general practitioners (GPs) and supports them to reconsider a patient’s presentation and/or diagnosis where the patient has attended a GP three or more times and symptoms have escalated, or the diagnosis is uncertain.

Jess’s Rule can be used to support a GP’s decision on an appropriate referral within the SPoA model. SPoA will provide a more efficient approach to triaging patients, with all appropriate requests and referrals, excluding urgent suspect cancer, flowing through a single ‘front door’. SPoA supports clinical triage to the most appropriate service or outcome, meaning timelier, more joined-up care for patients. Patients will still have a choice about where they receive care.

Safeguards within the SPoA model include senior clinical oversight of triage decisions and the ability for primary care clinicians to re‑escalate concerns where symptoms persist, worsen, or remain unexplained. These arrangements aim to ensure patients who require specialist assessment are not inappropriately managed in the community, and that shared clinical judgement remains central to decision‑making.

Under section 9(5) of the Care Act 2014, local authorities are required to involve the adult concerned and, where appropriate, their carers, family members, or others with an interest in their welfare, when carrying out a needs assessment and considering how care and support needs should be met.

Under the Care Act 2014, local authorities are also tasked with the duty to shape their care markets to meet the diverse needs of all local people. This includes commissioning a diverse range of care and support services that enable people to access quality care.

Local authorities should engage with people who draw on care and support, and their families and carers, to inform commissioning decisions and to consider the outcomes which matter to them. This is reflected in the Care and Support Statutory Guidance, which supports local authorities to fulfil their Care Act duties, including expectations around involvement and co‑production with people who draw on care and support and their families.

Under the Health and Care Act 2022, the Care Quality Commission has a statutory duty to assess how well local authorities are delivering their adult social care duties.

Advice and Guidance (A&G) is designed to support quicker, clearer clinical decision making, by enabling general practitioners (GPs) and specialists to discuss and agree on the most appropriate next steps for a patient. The 2026/27 GP Contract does not mandate the use of A&G in all circumstances. Instead, practices are expected to use A&G prior to or in place of a planned care referral, where clinically appropriate, and to follow locally agreed referral pathways.

In 2025/26 we introduced a £20 payment for GPs for each A&G request, allocating up to a total of £80 million of new funding, which has supported significant increases in A&G. For 2026/27, this funding is being incorporated into the GP Contract to provide a consistent, streamlined approach that recognises the vital role of GPs in delivering A&G. Embedding A&G in the GP Contract recognises it as routine clinical practice, removes annual signups, and provides more predictable funding while supporting consistent patient pathways.

We are investing £485 million in GPs in 2026/27, bringing the total spend on the GP Contract to over £13.8 billion. This builds on last year’s £1.1 billion of investment. This uplift represents a 3.6% cash increase, or 1.4% real terms increase, and includes an assumed pay increase of 2.5%. As with previous years, we have asked the independent pay review body for Doctors' and Dentists' Remuneration, for a pay recommendation for 2026/27 for the Government to consider.

The Department is holding the Care Quality Commission (CQC) to account for its performance and has strengthened oversight following Dr Penny Dash’s review of the CQC’s operational effectiveness, including improvements in timeliness of assessments.

The CQC has pledged to respond rapidly to urgent and extreme risks, prioritising services registered for over a year without assessment or inspection and those with outdated ratings. From January 2026, this refreshed approach will enable the CQC to prioritise settings, including care homes.

In the 2024/25 financial year, the CQC completed 2,292 assessments of adult social care services. From 1 April 2025 to 22 March 2026, the CQC completed 3,546 assessments of adult social care services, an increase of 55%.

The CQC is piloting a number of initiatives to increase the number of assessments they can deliver in adult care per year to ensure care settings are inspected regularly, and these will be rolled out in the first half of the 2026/27 financial year.

The Department is holding the Care Quality Commission (CQC) to account for its performance and has strengthened oversight following Dr Penny Dash’s review of the CQC’s operational effectiveness, including improvements in timeliness of assessments.

The CQC has pledged to respond rapidly to urgent and extreme risks, prioritising services registered for over a year without assessment or inspection and those with outdated ratings. From January 2026, this refreshed approach will enable the CQC to prioritise settings, including care homes.

In the 2024/25 financial year, the CQC completed 2,292 assessments of adult social care services. From 1 April 2025 to 22 March 2026, the CQC completed 3,546 assessments of adult social care services, an increase of 55%.

The CQC is piloting a number of initiatives to increase the number of assessments they can deliver in adult care per year to ensure care settings are inspected regularly, and these will be rolled out in the first half of the 2026/27 financial year.

Answering the question raised by the Hon. Member would require the Medicines and Healthcare Products Agency staff to go through a large volume of data manually. This is because the information is not held in such a way to be able to filter by the requested categories.

The sections (a) and (b) would require a data extraction to identify all reports received from members of the public over the last five years. Following this, a manual review would need to be undertaken of every report to cross reference the suspect drug against all active licenses at the time of reporting for each individual case and would thereby incur disproportionate cost. Section (c) is information which is not held in the Yellow Card database.

The Guide to Parliamentary Work sets here out that there is an advisory cost limit known as the disproportionate cost threshold which is the level above which departments can decide not to answer a written question. The Guide to Parliamentary Work is published online and is available at the following link:

https://www.gov.uk/government/publications/guide-to-parliamentary-work

The total cost of the Thirlwall Inquiry from its commencement in September 2023 to the end of March 2026 is £18,718,000.00. This includes March 2026 forecasted amounts.

My Rt Hon. Friend, the Secretary of State for Health and Social Care, has regular discussions with officials, external experts, and ministerial colleagues on a range of issues, including national security, defence, and resilience.

The Home Defence Programme was established in August 2024 to build the United Kingdom’s resilience to any potential escalation to conflict. It is an evolving and enduring programme of work which provides defence, security, and resilience planning, focused on aligning military and civil effort in the event of a period of crisis and international hostilities affecting the UK, informed by and reflecting the recommendations from Government strategies, including the Strategic Defence Review, National Security Strategy, and Resilience Action Plan.

The Department, with NHS England and health partners, is actively supporting this work. This includes working with partners to ensure the health sector has flexible, adaptable, and scalable capabilities that can respond to a range of threats such as equipment, for example stockpiles and countermeasures, medicines, and medical equipment, skilled people, such as clinicians and public health staff, and infrastructure, including technology, diagnostics, testing.

Liver disease is a broad term for several conditions affecting the liver and pancreas and the Government is taking decisive action to tackle ill health and shift the focus on diseases such as liver disease from treatment to prevention.

The most prevalent cause of liver-related ill health and death is alcohol-related liver disease. From 2026/27, all alcohol and drug treatment and recovery funding will be channelled through the Public Health Grant, with ringfenced funding in which Blackpool Council will receive £4,554,578 in 2026/27 and indicative totals of £4,647,350 and £4,737,845 for 2027/28 and 2028/29 respectively. The Department has also published the United Kingdom’s first clinical guidelines on alcohol treatment which include guidance on early identification of liver disease and treating alcohol dependence in people with liver disease. To help people make healthier choices about alcohol we are making it a legal requirement for alcohol labels to display health warnings and consistent nutritional information.

Locally, Blackpool Teaching Hospital’s Liver Service has recently achieved micro‑elimination of hepatitis C, with all drug and alcohol services across Lancashire now declared micro‑eliminated. The region’s Liver Health Check Team supports earlier detection of liver disease by referring at‑risk individuals, including those with high body mass index, diabetes, or high alcohol consumption for community fibroscans available in general practices (GPs), community venues, and via mobile units.

NHS England’s liver transformation programme focusses on awareness, prevention, diagnosis, detection, and treatment of all forms of liver disease and has developed a data pack for regional commissioners using the Department’s Fingertips data to support this. It is for commissioners in integrated care boards to determine how best to use this information as part of local commissioning decisions. The National Institute for Health and Care Excellence is assessing new treatments for metabolic dysfunction-associated steatotic liver disease (MASLD), the broader term for fat buildup of the liver, which metabolic dysfunction-associated steatohepatitis (MASH) falls under. This includes resmetirom and semaglutide. Outputs and recommendations are expected to be published mid-2026.

As part of our 10-Year Health Plan, we are improving diets, reducing physical inactivity, and creating healthier environments so that fewer people reach the point of needing treatment for diseases such as MASH. This includes updating the standards behind the advertising and promotions restrictions on ‘less healthy’ food and drink, requiring all large food businesses to report against standardised metrics on the healthiness of food sales and getting millions moving more through our national movement campaign.

Liver disease is a broad term for several conditions affecting the liver and pancreas and the Government is taking decisive action to tackle ill health and shift the focus on diseases such as liver disease from treatment to prevention.

The most prevalent cause of liver-related ill health and death is alcohol-related liver disease. From 2026/27, all alcohol and drug treatment and recovery funding will be channelled through the Public Health Grant, with ringfenced funding in which Blackpool Council will receive £4,554,578 in 2026/27 and indicative totals of £4,647,350 and £4,737,845 for 2027/28 and 2028/29 respectively. The Department has also published the United Kingdom’s first clinical guidelines on alcohol treatment which include guidance on early identification of liver disease and treating alcohol dependence in people with liver disease. To help people make healthier choices about alcohol we are making it a legal requirement for alcohol labels to display health warnings and consistent nutritional information.

Locally, Blackpool Teaching Hospital’s Liver Service has recently achieved micro‑elimination of hepatitis C, with all drug and alcohol services across Lancashire now declared micro‑eliminated. The region’s Liver Health Check Team supports earlier detection of liver disease by referring at‑risk individuals, including those with high body mass index, diabetes, or high alcohol consumption for community fibroscans available in general practices (GPs), community venues, and via mobile units.

NHS England’s liver transformation programme focusses on awareness, prevention, diagnosis, detection, and treatment of all forms of liver disease and has developed a data pack for regional commissioners using the Department’s Fingertips data to support this. It is for commissioners in integrated care boards to determine how best to use this information as part of local commissioning decisions. The National Institute for Health and Care Excellence is assessing new treatments for metabolic dysfunction-associated steatotic liver disease (MASLD), the broader term for fat buildup of the liver, which metabolic dysfunction-associated steatohepatitis (MASH) falls under. This includes resmetirom and semaglutide. Outputs and recommendations are expected to be published mid-2026.

As part of our 10-Year Health Plan, we are improving diets, reducing physical inactivity, and creating healthier environments so that fewer people reach the point of needing treatment for diseases such as MASH. This includes updating the standards behind the advertising and promotions restrictions on ‘less healthy’ food and drink, requiring all large food businesses to report against standardised metrics on the healthiness of food sales and getting millions moving more through our national movement campaign.

The Government recommends that adults consume 30 grams of fibre every day and that this should come from a variety of food sources. This is reflected in the United Kingdom’s national food model, the Eatwell Guide, which is a visual representation of Government advice on a healthy, balanced diet, and applies to most people from the age of two years old. The Eatwell Guide shows that we should base our diets on foods which are sources of fibre, for instance vegetables, fruit, and wholegrain or higher fibre starchy carbohydrate foods, as well as beans and pulses. The Eatwell Guide is available at the following link:

https://www.gov.uk/government/publications/the-eatwell-guide

The Eatwell Guide principles are communicated through a variety of channels, including the NHS.UK website and the Department’s social marketing campaigns Better Health, Better Health Families, and Best Start in Life. For example, the NHS.UK website features a page with advice on the health benefits of dietary fibre and how to get more fibre into your diet, with further information available at the following link:

https://www.nhs.uk/live-well/eat-well/digestive-health/how-to-get-more-fibre-into-your-diet/

The Department, through the National Institute for Health and Care Research, is funding research into the health effects of diet on children and adults, including the effects of fibre. This includes a study which seeks to understand how the diet of children in the UK influences their health in childhood, adolescence, and early adulthood.